Format
Sealed research vial
Trust signal
COA-backed inventory
99%+ Purity
Lab-grade supply. Limited AU stock.
A$329
Select options below
Size
Select one
Select your preferred options to continue.
Fast AU dispatch, tracked delivery, and documentation-ready inventory.
Why labs buy from APL
High purity, consistent supply, and fast AU-wide dispatch.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
IGF-1 LR3 is an engineered 83-amino acid IGF-1 analog (Long-R3-IGF-1) with an Arg3 substitution and a 13-amino acid N-terminal extension that reduces insulin-like growth factor binding protein (IGFBP) affinity by approximately 500-fold.
The IGFBP bypass property is both the main experimental advantage and a design consideration — cell assays using IGF-1 LR3 are not directly comparable to assays using native IGF-1 because IGFBP buffering is absent. Researchers studying the modulating role of IGFBPs often deliberately compare LR3 against native IGF-1 to attribute differences in downstream readouts to IGFBP interference.
Browse Inventory
In research literature, IGF-1 LR3 is generally treated as an engineered 83-amino acid IGF-1 analog (Long-R3-IGF-1) with an Arg3 substitution and a 13-amino acid N-terminal extension that reduces insulin-like growth factor binding protein (IGFBP) affinity by approximately 500-fold. IGF-1 LR3 retains near-native binding affinity for the IGF-1 receptor (IGF-1R) — a receptor tyrosine kinase that autophosphorylates on ligand binding and recruits IRS-1 for PI3K/Akt and Grb2-SOS for MAPK/ERK activation — but bypasses IGFBP-mediated sequestration in cell culture medium. This dramatically extends its effective half-life in serum-containing assay systems relative to native IGF-1, making it the preferred choice for cell-based proliferation, differentiation, and survival assays where IGFBP-3 and other binding proteins would otherwise limit bioavailability. The Arg3 substitution specifically reduces IGFBP-3 binding without substantially altering IGF-1R kinetics.
The IGFBP bypass property is both the main experimental advantage and a design consideration — cell assays using IGF-1 LR3 are not directly comparable to assays using native IGF-1 because IGFBP buffering is absent. Researchers studying the modulating role of IGFBPs often deliberately compare LR3 against native IGF-1 to attribute differences in downstream readouts to IGFBP interference. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether IGF-1 LR3 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.
Potential research applications for IGF-1 LR3 should be framed strictly in analytical and laboratory terms. Typical reasons a team might review this product page include:
Handling decisions should always follow the vial label, internal SOPs, and any product-specific documentation. A conservative laboratory baseline for IGF-1 LR3 is:
If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.
When teams compare IGF-1 LR3 with TA-1, Melanotan 1, and Klow, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.
Certificate of Analysis
COA library
Browse the current COA library and available product documentation.
It brings together 2 labelled variants: 0.1mg and 1mg, current pricing context, stock visibility, COA access, and internal links to related catalogue pages so a laboratory buyer can review the material from a single reference URL.
IGF-1 LR3 is generally discussed as an engineered 83-amino acid IGF-1 analog (Long-R3-IGF-1) with an Arg3 substitution and a 13-amino acid N-terminal extension that reduces insulin-like growth factor binding protein (IGFBP) affinity by approximately 500-fold. The most relevant background is sequence behaviour, pathway or receptor context where documented, and analytical consistency under controlled laboratory conditions.
Use the label, COA, and internal SOPs as the primary guide. In general, store the material under controlled laboratory conditions, minimise avoidable environmental exposure, and keep variant tracking records current.
This page links the broader COA library when a product-specific document is not attached. Laboratories should use the published documentation set that is currently available for the listing.
No. The page should be interpreted strictly in a research and laboratory context. It does not provide dosage guidance, treatment claims, or human or animal use instructions.
